NCT04345094 is a NA clinical trial of Hexylresourcinol in Photoaging, sponsored by Sytheon Ltd..

Who is sponsoring NCT04345094?

NCT04345094 is sponsored by Sytheon Ltd..

What drugs are being tested in NCT04345094?

Interventions in NCT04345094: Hexylresourcinol, Hydroquinone.

What condition does NCT04345094 study?

NCT04345094 studies Photoaging.

Is NCT04345094 still recruiting?

NCT04345094 is currently completed. Last updated 10 July 2020.

Last reviewed 2020-07-10 · How we verify

NCT04345094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Hexyresorcinol vs Hydroquinone for Photoaging

Completed NA Last updated 10 July 2020

What this trial tests

NA trial testing Hexylresourcinol in Photoaging in 32 participants. Completed in 15 February 2020.

Timeline

1 July 2019

Primary endpoint
24 December 2019

15 February 2020

Quick facts

Lead sponsor	Sytheon Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	1 July 2019
Primary completion	24 December 2019
Estimated completion	15 February 2020
Sites	1 location across United States

Drugs / interventions tested

Hexylresourcinol
Hydroquinone (HYDROQUINONE) — full drug profile →

Conditions studied

Photoaging — all drugs for Photoaging →

Sponsor

Sytheon Ltd.

Who can join

Adults 35 to 65, female only, with Photoaging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Photoaging is a common concern within the cosmeceutical industry with many products that are available. One frequently used product is hydroquinone that is used to even skin tone. However, hydroquinone has several shortcomings. The ingredient is controversial for its potential safety issues and it has been banned in Europe. An alternative ingredient that has emerged for its potential use is hexyresorcinol for evening skin tone. Additionally, hexylresorcinol may have other photoaging benefits such as the reduction in the appearance of fine lines. Therefore, the aim of this study is to assess how hexyresorcinol may compare to the use of hydroquinone in the setting of photoaging.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Prospective, randomized, double-blind clinical study of split-body comparison of topical hydroquinone and hexylresorcinol for skin pigment appearance.
Wu H, Gabriel TA, Burney WA, Chambers CJ, et al · · 2023 · cited 9× · PMID 36502500 · DOI 10.1007/s00403-022-02514-0

Verify or expand the search:

Other recruiting trials for Photoaging

Currently open trials in the same condition.

NCT06029725 — RFMN in Combination With 1927 nm Thulium Laser for Treating Photoaged Skin · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04345094 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sytheon Ltd.
Last refreshed: 10 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04345094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing